PLIANT THERAPEUTICS, INC.
PLRXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M | $41.8M |
| Operating income | −$156.4M | −$228.4M | −$184.1M | −$127.2M | −$97.5M | −$41.6M |
| Net income | −$149.3M | −$210.3M | −$161.3M | −$123.3M | −$97.3M | −$41.5M |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M | $295.5M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M | $12.5M |
| Equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M | $283.1M |
| EPS (diluted) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.95 |
| Shares out. | 61.2M | 60.2M | 58.9M | 36.1M | 35.7M | 35.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −82.4%
- Return on assets
- −66.3%
- Return on capital (ROCE)
- −74.9%
- Liabilities / assets
- 19.5%
- Debt / equity
- 0.24×
- Book value / share
- $2.96
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -7.54distress
- Accruals / assets
- −9.3%clean
- Piotroski F-Score
- 3/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Altman Z″ in the distress zone
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Point72 Asset Management, L.P.Passive (13G)Feb 17, 2026
- Woodline Partners LpPassive (13G)Feb 17, 2026
- Citadel Advisors LlcPassive (13G)Feb 9, 2026
- Morgan StanleyPassive (13G)Jan 8, 2026
- Deep Track Capital, LpPassive (13G)Nov 14, 2025
- Vanguard Group IncPassive (13G)Jul 29, 2025
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Paradigm Biocapital Advisors LpPassive (13G)May 15, 2025
- Price T Rowe Associates Inc /Md/Passive (13G)May 14, 2025
- Tang Capital Management LlcActivist (13D)Mar 10, 2025
- Fmr LlcPassive (13G)Mar 7, 2025
- Redmile Group, LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Cummings Keith LamontOfficer — Chief Financial Officer | Jan 20, 2026 | Sell | 24,002 | $1.28 |
| Cheung LilyOfficer — Chief Human Resource Officer | Jan 20, 2026 | Sell | 7,534 | $1.28 |
| Coulie BernardOfficer — President and CEO | Jan 20, 2026 | Sell | 89,375 | $1.28 |
| Kuo MinnieOfficer — Chief Operating Officer | Jan 20, 2026 | Sell | 6,917 | $1.28 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.4M | 10.4 | +0.4% |
| Apr 30, 2026 | 3.4M | 5.3 | -5.8% |
| Apr 15, 2026 | 3.6M | 10.4 | -9.6% |
| Mar 31, 2026 | 4.0M | 7.2 | +6.0% |
| Mar 13, 2026 | 3.8M | 7.9 | +0.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Director / officer changeApr 17, 2026
- Other material eventMar 30, 2026
- Results of operationsMar 11, 2026
- Entered a material agreement · Modified shareholder rightsMar 3, 2026
- Director / officer changeDec 16, 2025
- Director / officer changeDec 8, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.